The ability to differentiate brain injury type and stage, especially when the etiology of injury or stage of progression is unknown, is of important clinical relevance to the treatment of stroke given the limited time window with which tPA can be administered following an ischemic event, and given that it is contraindicated for hemorrhagic stroke [227]. This evidence concerns the gene PLAT and Stroke.